Skip to content
  • Home
  • About
  • News
    • Top
    • Recent News
    • Archive
  • Account
    • Profile
    • Manage Corporate Account
    • Orders
    • Billing
    • Cancel
  • Subscription Plans
  • Contact
  • Login
  • Home
  • About
  • News
    • Top
    • Recent News
    • Archive
  • Account
    • Profile
    • Manage Corporate Account
    • Orders
    • Billing
    • Cancel
  • Subscription Plans
  • Contact
  • Login

Discovery’s Interim Results Highlight Strong Growth

Learn how Discovery’s interim results reflect a 22% increase in normalised profit, demonstrating resilience in a fluctuating market.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Life Healthcare Share Price Stumbles Following R2.9bn Liability Adjustment

Life Healthcare share price falls 9% due to R2.9bn adjustment linked to the Piramal liability affecting investor sentiment.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Ascendis Health Exits JSE and Positions for Growth

Ascendis Health exits JSE following a strong investor mandate as part of its turnaround strategy aimed at unlocking value.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen Unlocking Value with New Manufacturing Strategies

Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Mediclinic AI Strategy Targets R2 Billion Savings Amid Job Freezes

Explore the Mediclinic AI strategy aimed at R2 billion in savings by 2027 through Artificial Intelligence integration.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

SA Pharma Sector Unfazed by US Tariffs Impact

The SA pharma sector is unfazed by US tariffs, as key leaders assess the situation, ensuring stability and security in the market.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here